Who dies from sarcoidosis and why?

American Journal of Respiratory and Critical Care Medicine

Volumn 183, Issue 11, 2011, Pages 1446-1447

  Baughman, Robert P ^a   Lower, Elyse E ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH CERTIFICATE; EDITORIAL; LUNG DISEASE; MORTALITY; PRIORITY JOURNAL; RESPIRATORY FAILURE; SARCOIDOSIS; UNITED STATES;

CAUSE OF DEATH; CONTINENTAL POPULATION GROUPS; ETHNIC GROUPS; FEMALE; HUMANS; MALE; RISK FACTORS; SARCOIDOSIS; SEX DISTRIBUTION;

EID: 79957940338     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201103-0409ED     Document Type: Editorial

References (16)

1. Baughman RP, Judson MA, Teirstein A, Yeager H, Rossman M, Knatterud GL, Thompson B. Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM 2006;99:307-315.
2. Reich JM. Mortality of intrathoracic sarcoidosis in referral vs population-based settings: influence of stage, ethnicity, and corticosteroid therapy. Chest 2002;121:32-39. (Pubitemid 34114225)
3. Swigris JJ, Olson AL, Huie TJ, Fernandez-Perez ER, Solomon J, Sprunger D, Brown KK. Sarcoidosis-related mortality in the United States from 1988-2007. Am J Respir Crit Care Med 2011;183:1524-1530.
4. Gideon NM, Mannino DM. Sarcoidosis mortality in the United States 1979-1991: an analysis of multiple-cause mortality data. Am J Med 1996;100:423-427.
5. Foreman MG, Mannino DM, Kamugisha L, Westney GE. Hospitalization for patients with sarcoidosis: 1979-2000. Sarcoidosis Vasc Diffuse Lung Dis 2006;23:124-129.
6. Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006;61:980-985. (Pubitemid 44787169)
7. Baughman RP, Nagai S, Balter M, Costabel U, Drent M, du Bois RM, Grutters JC, Judson MA, Lambiri I, Lower EE, et al. Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG task force. Sarcoidosis Vasc Diffuse Lung Dis 2011; (in press).
8. Baughman RP, Winget DB, Bowen EH, Lower EE. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis 1997;14: 154-158. (Pubitemid 27427348)
9. Chappell AG, Cheung WY, Hutchings HA. Sarcoidosis: a long-term follow up study. Sarcoidosis Vasc Diffuse Lung Dis 2000;17:167-173.
10. Perry A, Vuitch F. Causes of death in patients with sarcoidosis: a morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med 1995;119:167-172.
11. Nicholson TT, Plant BJ, Henry MT, Bredin CP. Sarcoidosis in Ireland: regional differences in prevalence and mortality from 1996-2005. Sarcoidosis Vasc Diffuse Lung Dis 2010;27:111-120.
12. Shu X, Ji J, Sundquist K, Sundquist J, Hemminki K. Survival in cancer patients with previous hospitalization for sarcoidosis: a Swedish population-based cohort study during 1964. Ann Oncol (In press)
13. Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 2010;138:1078-1085.
14. Baughman RP, Lower EE. Fungal infections as a complication of therapy for sarcoidosis. QJM 2005;98:451-456. (Pubitemid 40796817)
15. Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, Du BR, Albera C, Brutsche M, Davis G, Donohue JF, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006;174:795-802. (Pubitemid 44511661)
16. Milman N, Andersen CB, Baslund B, Loft A, Iversen M. Does tumour necrosis factor-alpha inhibitor infliximab induce histological resolution of pulmonary sarcoid granulomas? Clin Respir J 2007;1: 106-113.